The Cleveland Cord Blood Center (CCBC) is an independent, public cord blood bank. Since its founding in 2008, the not-for-profit 501(c)(3) collects, processes, stores and distributes stem-cell rich umbilical cord blood for transplantation in patients with life threatening disorders such as leukemia, lymphoma and immune system disorders. The Cleveland Cord Blood Center was founded by Mary J. Laughlin, M.D., who performed one of the world’s first successful umbilical cord blood stem cell transplants on an adult leukemia patient in 1995.
On September 1, 2016, the CCBC received a biologics license from the U.S. Food and Drug Administration (FDA) for CLEVECORD, a stem cell product derived from umbilical cord blood for use in stem cell transplants. The FDA approval of CLEVECORD reflects the organization’s ability to meet the highest quality standards in the industry for distribution of cord blood products to transplant centers throughout the U.S. and around the world.
Up to 50 percent of parents giving birth in CCBC’s partner hospitals donate their baby’s umbilical cord blood, a rate well above the national average.
The broad diversity in the genetic and ethnic backgrounds of families in Atlanta, Cleveland and San Francisco donating cord blood to the Cleveland Cord Blood Center supports creation of an inventory of suitable cord blood units for patients of African American, Latino and Asian descent, for whom well-matched stem cell grafts are not generally available in the adult donor registry.
Located at the Global Cardiovascular Innovation Center in Cleveland (GCIC), CCBC scientists are conducting innovative research in the development of stem cell treatments to address unmet medical needs in patients suffering from Parkinson’s disease, diabetes, HIV/AIDS and those with wound healing issues.